Easton Pharmaceuticals Announces the Appointment of Evan Karras as CEO / Director and Mr. Nunzio Valerie as President / CFO; Mr. Karras Possesses a Strong Background in Canadian and International Commercial Successes and Is Expected to Make Major Impact on Implementation of Easton’s Business Plan

TORONTO, ON–(Marketwired – Jul 29, 2015) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces the appointment of Evan Karras as CEO & Director and announces Mr. Nunzio Valerie as President and Director.

Continue reading Easton Pharmaceuticals Announces the Appointment of Evan Karras as CEO / Director and Mr. Nunzio Valerie as President / CFO; Mr. Karras Possesses a Strong Background in Canadian and International Commercial Successes and Is Expected to Make Major Impact on Implementation of Easton’s Business Plan

Easton Pharmaceuticals / BMV Medica Announces Its Mexican Ministry of Health and Latin America Regulatory Filing and Approval Process for Cancer Drugs Paclitaxel and Docetaxel From Biolyse Pharma Has Been Shortened

TORONTO, ON–(Marketwired – Jul 6, 2015) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces positive update from Ackerman Pharma; where the regulatory filing and anticipated approval process for the cancer drugs Paclitaxel and Docetaxel has been shortened.

Continue reading Easton Pharmaceuticals / BMV Medica Announces Its Mexican Ministry of Health and Latin America Regulatory Filing and Approval Process for Cancer Drugs Paclitaxel and Docetaxel From Biolyse Pharma Has Been Shortened

Easton Pharmaceuticals and BMV Medica Announce Eva Pro as Brand Name for Its Line of Patented Women’s Diagnostic Tests for the Mexican and Other Latin American Markets; Trademark Registration of Individual Product Names, Logos and Packaging Has Commenced

TORONTO, ON–(Marketwired – Jun 23, 2015) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces that Easton and BMV have decided on Eva Pro as brand name for its line of patented women’s diagnostic tests for Mexico and possibly the Latin American market. The Eva Pro brand will include both the already secured vaginal infection diagnostic test and most likely the amniotic fluid leak test for late pregnancy. Easton / BMV move toward Trademarking and provides update on Latin American market.

Continue reading Easton Pharmaceuticals and BMV Medica Announce Eva Pro as Brand Name for Its Line of Patented Women’s Diagnostic Tests for the Mexican and Other Latin American Markets; Trademark Registration of Individual Product Names, Logos and Packaging Has Commenced

Easton Pharmaceuticals Announces Finalized Joint Partnership Agreement With BMV Medica for Exclusive Rights to Distribute World Patented Women’s Health Diagnostic Test in Mexico From Israel-Based Common Sense Ltd.

The VS-Sense Diagnostic Product Line Currently Holds Extended Patent Protection and Is Expected to Generate Well Over 100% Profit Margins for Easton / BMV; The Vaginal Health Test Is Currently Sold throughout the United States, Canada and Soon Europe.

Continue reading Easton Pharmaceuticals Announces Finalized Joint Partnership Agreement With BMV Medica for Exclusive Rights to Distribute World Patented Women’s Health Diagnostic Test in Mexico From Israel-Based Common Sense Ltd.

Easton Pharmaceuticals Announces Signed Agreement With Medicated Markets International LLC, A Major California-Based Medical Marijuana Grower

TORONTO, ON–(Marketwired – Dec 31, 2014) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces it has signed an agreement with Medicated Markets International LLC., a major California medical marijuana grower.

Continue reading Easton Pharmaceuticals Announces Signed Agreement With Medicated Markets International LLC, A Major California-Based Medical Marijuana Grower

Easton Pharmaceuticals Nears Its $1,000,000 Finance Limit for Year, Moves Towards SEC Filing to Receive up to $5,000,000 in Financing; Closes on Medical Marijuana Agreement

TORONTO, ON–(Marketwired – Mar 11, 2014) – Easton Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, today announces it nearing its limit on financing under regulation offerings.

Continue reading Easton Pharmaceuticals Nears Its $1,000,000 Finance Limit for Year, Moves Towards SEC Filing to Receive up to $5,000,000 in Financing; Closes on Medical Marijuana Agreement